UBS Group’s Medifast MED Stock Holding History

UBS Group’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-21,500	Closed	-$2.98M	–	8249
2020 Q2	$2.98M	Buy	+21,500	New	+$1.97M	﹤0.01%	2503

Other funds holding MED

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SCP

Steamboat Capital Partners Rye, New York $468M AUM 80.81% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group's MED Position: Q2 2026 in Review

UBS Group increased its Medifast (MED) stake by 263% in Q2 2026, buying an estimated $420K and bringing the position to 50,223 shares worth $533K. The position accounts for ﹤0.01% of the portfolio, ranked #6187.

UBS Group first reported a position in MED in Q4 2014 and has held it in 47 quarters since. The position peaked at $6.49M in Q2 2023. 112 funds tracked by Wall St. Rank hold MED as of Q2 2026.

UBS Group held 50,223 shares of Medifast worth $533K as of Q2 2026.
UBS Group bought 36,390 Medifast shares in Q2 2026, an estimated $420K.
Medifast made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6187 holding.
UBS Group first reported a position in Medifast in Q4 2014 and has held it in 47 quarters since.
UBS Group's Medifast position peaked at $6.49M in Q2 2023.
112 funds tracked by Wall St. Rank held Medifast as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.